Akero Therapeutics: A Very Attractive Risk/Reward Opportunity [Seeking Alpha]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
SummaryAK-001 recently released data has high likelihood to correlate with future biopsy data.The company is in the eve of a new stage.Akero Therapeutics may lead in the NASH market in future.In our previous assessment, we compared 13 NASH drug candidates, and our favorite was AK-001 of Akero Therapeutics (NASDAQ:AKROclick hereReleased data confirmed our previous assessment. Now, we would like to draw a more detailed conclusion about Akero Therapeutics, its drug candidate, and possible future prospects. We would like to share our opinion why we are still holding our long positions and why the company's stock price has high upside potential.Akero Therapeutics is focused on metabolic disorders, and the lead drug candidate A
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities InvestigationAccesswire
- Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to ConnectAccesswire
- Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLDGlobeNewswire
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach OutAccesswire
AKRO
Earnings
- 11/8/24 - Miss
AKRO
Sec Filings
- 1/10/25 - Form 4
- 1/6/25 - Form 4
- 1/2/25 - Form 144
- AKRO's page on the SEC website